Scientific deep-dive

GLP-1 Drugs, Testosterone and Male Fertility: Where the Evidence Splits

In a randomized comparison, semaglutide improved sperm morphology while testosterone replacement significantly reduced sperm counts, though both raised testosterone.

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
7 min read·4 citations

Almost everything written about these drugs and reproduction is about women. The men’s evidence is thinner, and it contains one surprising result: in a randomized comparison, semaglutide improved sperm morphology while testosterone replacement therapy significantly reduced sperm concentration and total count, even though both raised total testosterone.[1] If you are on TRT and hoping to father a child, this matters. The erectile function evidence is messier, and points both ways.

Why weight matters here at all

Excess body fat lowers testosterone through a fairly well-understood route: fat tissue converts testosterone to estradiol, and the resulting signal suppresses the hormonal axis that tells the testes to produce more. The clinical name for the result is functional hypogonadism, meaning low testosterone with no disease of the testes themselves.

The word doing the work is functional. It means the machinery is intact and the signal is being suppressed, which in turn means losing weight can reverse it. That is the mechanism through which any effective weight-loss drug could raise testosterone without acting on the hormone directly.

The trial that compared the two options

A randomized open-label trial put semaglutide against testosterone replacement therapy in 25 men with type 2 diabetes, obesity and functional hypogonadism, men who in ordinary practice would be offered TRT.[1] Baseline sperm quality across the group was poor, below the fifth percentile of reference values.

Semaglutide against testosterone replacement, 25 men with type 2 diabetes, obesity and functional hypogonadism.
SemaglutideTestosterone replacement
Morphologically normal spermRose from 2% to 4% (p = 0.012)—
Sperm concentrationHigher than TRTSignificantly decreased
Total sperm numberHigher than TRTSignificantly decreased
Total testosteroneIncreasedIncreased

Both treatments did what they were prescribed for, but only one did it without cost to fertility.

Endocrinologists expect this; many patients do not. Exogenous testosterone suppresses the signal that drives sperm production, which is the basis of research into male hormonal contraception. If you are on TRT, or weighing one of the online TRT clinics, and children are a possibility, that belongs in the conversation before the first injection. This trial randomized 25 men and ran open-label, so it is a reason to ask the question, not an answer to it.

Erectile function: the evidence disagrees

  • Against these drugs: a TriNetX database study of non-diabetic obese men aged 18 to 50 prescribed semaglutide for weight loss found an increased risk of a subsequent erectile dysfunction diagnosis, in men with no prior ED history.[2] The authors note sexual dysfunction already appears in package inserts, and that nobody had quantified it.
  • For them: a second TriNetX study in men with type 2 diabetes found tirzepatide associated with reduced ED risk against every comparator (risk ratio 0.70 against sitagliptin and 0.67 against injectable semaglutide).[3]

Those are less contradictory than they first appear. Both studies place semaglutide worse than whatever it is compared with; the second finds tirzepatide better than semaglutide specifically. The randomized trial above also measured erectile function, and scores improved significantly only on testosterone replacement, not on semaglutide.[1] So a defensible reading is that the drugs may differ from one another, rather than that the class is uniformly good or bad.

A defensible reading is not a finding. Both are retrospective analyses of the same commercial database, in different populations, and neither randomized anything. Erectile dysfunction is also diagnosed when someone raises it, which makes it unusually sensitive to how often a man is seeing a doctor. Starting a new weight-loss drug means seeing one more often.

Erectile dysfunction is diagnosed when someone raises it, and starting a new weight-loss drug means seeing a doctor more often.

What the systematic review concludes

A 2026 systematic review in the Journal of Sexual Medicine gathered the randomized trials and cohort studies of GLP-1 drugs on male reproductive hormones, semen parameters and metabolic outcomes across liraglutide, semaglutide, dulaglutide and exenatide.[4] It included 10 studies of 639 men. Its conclusion is that these drugs may improve testosterone levels and potentially enhance semen quality in men with metabolic issues, and that longer controlled studies are needed.

“May” and “potentially” are the operative words, and they are the reviewers’ own. This is a field with a handful of small studies, not a settled answer.

What to take from it

  • If low testosterone is the problem and weight is a driver, ask whether treating the weight is an alternative to treating the hormone, rather than assuming TRT is the only route.
  • If fertility matters to you now or later, raise it before starting testosterone replacement. The fertility cost of TRT is well established and is not a reason to avoid it, only a reason to plan around it.
  • If sexual function changes after starting a GLP-1, report it. The evidence is unsettled, which makes your prescriber’s judgment more important. The ED evidence is in GLP-1 drugs and erectile dysfunction, and what is known about desire is in GLP-1s and sex drive.
  • Do not read a 25-man trial as a treatment plan. It is a reason for a conversation and for larger studies.

The first of those questions is easier to ask where both treatments are on the menu. PeterMD, LaSara Medical Group and Ryze Rx sell compounded GLP-1s alongside TRT. TRT Nation is a testosterone clinic that also sells compounded tirzepatide, and Evolve Telemed runs weight care beside TRT and other hormone programs. DadVantage Men’s Health, a Florida practice led by a nurse practitioner, adds GLP-1 care to its testosterone and sexual-health services. Whoever you see, raise the fertility question yourself. Our boards for men, one for semaglutide and one for tirzepatide, rank every seller we track and carry the trial figures from this page. A narrower board, GLP-1 and testosterone providers, lists only the sellers whose own sites show a testosterone program.

The same goes for sexual function. MyDrHank sells ED medication next to compounded semaglutide, including a daily tablet compounded with the anti-nausea drug ondansetron, so a change can be raised with the prescriber who already handles both.

For the corresponding questions on the other side, our preconception timing article covers the interval before a planned pregnancy, and the PCOS piece deals with the female fertility evidence. Claims that these drugs change penis size are a separate question, about fat over the pubic bone rather than hormones: see what weight loss does to visible length.

Frequently Asked Questions

In men whose low testosterone is driven by excess weight, yes. In the randomized comparison, total testosterone rose on semaglutide as well as on testosterone replacement. The mechanism is indirect: fat tissue converts testosterone to estradiol and suppresses the hormonal axis, so losing weight relieves the suppression.
For fertility specifically, one 25-man randomized trial suggests it may be. Semaglutide increased morphologically normal sperm from 2% to 4%, while testosterone replacement significantly decreased sperm concentration and total count. Both raised testosterone. That is a single small open-label trial, so it is a reason to ask your clinician, not a basis for switching.
Exogenous testosterone suppresses the signal driving sperm production, which is well established and is the basis of research into male hormonal contraception. It is not a reason to avoid TRT, but it is a reason to raise fertility plans before starting it.
The evidence disagrees. One database study of non-diabetic men prescribed semaglutide for weight loss found increased risk of a new ED diagnosis. Another found tirzepatide associated with reduced risk against every comparator, including semaglutide. Both are retrospective and neither randomized anything, and diagnosis rates partly measure how often someone sees a doctor. In the small randomized trial against testosterone replacement, erectile function scores improved significantly only on testosterone.
No GLP-1 is approved for that and the evidence is one small trial. What the research supports is asking whether weight is driving the hormonal problem, and if so, whether treating the weight addresses it. That is a question for a clinician who can measure rather than infer.

References

  1. 1.Gregorič N, Šikonja J, Janež A, Jensterle M. Semaglutide improved sperm morphology in obese men with type 2 diabetes mellitus and functional hypogonadism Diabetes, Obesity and Metabolism. 2025. PMID: 39511836.
  2. 2.Able C, Liao B, Saffati G, et al. Prescribing semaglutide for weight loss in non-diabetic, obese patients is associated with an increased risk of erectile dysfunction: a TriNetX database study International Journal of Impotence Research. 2025. PMID: 38778151.
  3. 3.Cowart K, Murphy C, Carris N. Association of tirzepatide with erectile dysfunction in people with type 2 diabetes Journal of Diabetes and Its Complications. 2025. PMID: 40614622.
  4. 4.Deameh MG, Ramez M, Rowaiee R, et al. Effects of glucagon-like peptide-1 receptor agonists on male reproductive hormones, semen parameters, and metabolic outcomes: a systematic review The Journal of Sexual Medicine. 2026. PMID: 41498523.

Jardiance or Farxiga With Ozempic or Mounjaro: Taking an SGLT2 and a GLP-1

SGLT2 inhibitors like Jardiance and Farxiga are routinely taken with Ozempic or Mounjaro, and no label forbids it. Sugar and weight effects add up in trials; heart and kidney gains rest on subgroups. The real overlap is dehydration and ketoacidosis.

12 min read

MOTS-c: What the Evidence Shows, and What FDA Found

MOTS-c slowed weight gain and improved insulin sensitivity in mice. No published trial has given it to people, and there is no established human dose. The 503A bulks list leaves it out; under an interim HHS policy dated October 2026, HHS does not intend to take enforcement action against 503A compounding under strict conditions.

11 min read

AOD-9604: What the Evidence Shows

AOD-9604, a growth hormone fragment, failed its obesity trials: in 536 adults, weight loss beyond placebo was under 1 kg and the developer ended the program in 2007. FDA advisers voted 12 to 0 against compounding it.

9 min read

GLP-1 Drugs in Cushing's Syndrome: Weight Down, Cortisol Unchanged

A multicenter retrospective study of 20 adults with Cushing's syndrome found weight down 10.3 kg and HbA1c down 0.5% over a median 13 months, with ACTH and cortisol levels stable throughout.

5 min read

GLP-1 Drugs and Suicidal Thoughts: The Warning Came Off in 2026

In February 2026 the Suicidal Behavior and Ideation section was removed from the Wegovy, Zepbound and Saxenda labels, after three large studies looked for a signal and none found one.

7 min read

Exenatide (Byetta, Bydureon): The First GLP-1, Its Weight Loss and Where It Went

Exenatide, sold as Byetta and Bydureon BCise, was the first GLP-1 drug. It is approved only for type 2 diabetes, produces far less weight loss than semaglutide, and both brands are discontinued in the US. Its one generic is now listed as discontinued too.

10 min read